Tenaya Therapeutics (TNYA) Is Up 47.7% After Positive TN-301 DMD Data And Alnylam Deal [Yahoo! Finance]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Yahoo! Finance
1 data for its HDAC6 inhibitor TN-301 in Duchenne muscular dystrophy and cardiomyopathy, alongside a new research collaboration with Alnylam Pharmaceuticals in cardiovascular genetics. The comparison of TN-301 against the approved pan-HDAC inhibitor givinostat, showing stronger preclinical muscle and cardiac effects without similar side-effect signals, positions Tenaya's HDAC6-focused approach as a potentially differentiated entry in DMD-related and broader cardiovascular treatment research. We will now examine how TN-301's encouraging Duchenne muscular dystrophy data could reshape Tenaya's investment narrative following recent share price moves. The future of work is here. Discover the 28 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. What Is Tenaya Therapeutics' Investment Narrative? To own Tenaya Therapeutics, you really have to believe in the long-term value of its cardiomyopathy and rare disease gene therapy
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- Alnylam Pharmaceuticals (ALNY) had its "hold" rating reaffirmed by Jefferies Financial Group Inc.. They now have a $330.00 price target on the stock.MarketBeat
- Amvuttra (Medison Pharma, Alnylam Pharmaceuticals) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]Yahoo! Finance
- Alnylam to Webcast TTR Investor Webinar [Yahoo! Finance]Yahoo! Finance
- Alnylam to Webcast TTR Investor WebinarBusiness Wire
- Alnylam Tenaya Cardiovascular RNAi Pact And What It Means For Valuation [Yahoo! Finance]Yahoo! Finance
ALNY
Earnings
- 2/12/26 - Beat
ALNY
Sec Filings
- 3/6/26 - Form 4
- 3/6/26 - Form 4
- 3/6/26 - Form 4
- ALNY's page on the SEC website